A pharmacokinetic drug?drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects

Purpose In vitro data showed that selexipagand its active metabolite(ACT-333679) have an inductive effecton CYP3A4, CYP2B6, and CYP2C9at concentrations approximately 100-fold higher than the maximum plasma concentration (C max) measured under steady-state conditions. In order to confirm in vivo the lack of induction at the enterocytelevel, we assessed the effect of selexipagon midazolam, a substrate of hepatic and intestinal CYP3A4.